Articles by Larissa Ku
Panlin raises $148m for China VC fund
Shanghai-based venture capital firm Panlin Capital has raised RMB1 billion ($148 million) in its latest early-stage fund having spent about 16 months in the market.
Fund focus: A window of opportunity
With $600 million in dry powder in its third Huaxing Growth Capital US dollar-denominated fund, China Renaissance has demonstrated a willingness to deploy while others hold back
China drug developer Sumgen raises $32m
Addor Capital has led a RMB220 million ($32 million) Series B funding round for Hangzhou-based drug developer Sumgen Biotech.
Tencent backs Chinese healthcare cloud services platform
Kyee Technology, a Chinese digital medical platform has raised RMB430 million ($64 million) in a Series D round led by Tencent Holdings. Other investors include Longmen Capital, Dyee Capital and Royal Sea Capital.
Chinese mouse-based drug testing specialist raises $143m
Biocytogen, a Chinese contract research organization (CRO) that provides genetically-modified mice for drug testing, has raised RMB970 million ($143 million) in an extended tranche of Series D funding.
Long Hill invests $30m in Chinese O2O pharmacy player
Chinese digital healthcare platform inCarey has raised $30 million in an extended tranche of Series B funding from Long Hill Capital.
LP interview: Canada Pension Plan Investment Board
For Canada Pension Plan Investment Board, COVID-19 has reinforced the key tenets of its Asia investment strategy, from being flexible on timeline to putting boots on the ground
Chinese educational platform Lele Ketang raises $40m
Lele Ketang, a Chinese K12 education platform, has raised a $40 million Series C round led by Owl Ventures, the largest education-focused VC in the US.
GPs join $516m investment in Evergrande's EV unit
Evergrande New Energy Vehicle (NEV), a subsidiary of Chinese real estate developer Evergrande Group, has raised HK$4 billion ($516 million) from investors including Tencent Holdings, Sequoia Capital China, Yunfeng Capital, and Didi Chuxing.
GL Ventures leads $58m Series B in China's GemPharmatech
GemPharmatech, a Chinese company that provides genetically-modified mice for use in drug tests, has raised RMB400 million ($58.6 million) Series B led by GL Ventures, the VC arm of Hillhouse Capital.
China fresh produce retail: Changing channels
From online grocers to group buying platforms, capital is pouring into China’s fresh produce space as e-commerce finally makes it mark. Which business model will prevail?
China Renaissance closes third US dollar fund at $600m
China Renaissance has closed the third US dollar-denominated fund under its flagship Huaxing Growth Capital private equity platform at $600 million.
China autonomous driving: Dimension jump
There are no arguments about the transformational potential of autonomous driving in China, but investors have different ideas about where to find value
China's LandSpace raises $175m Series C
Chinese commercial rocket developer LandSpace has raised RMB1.2 billion ($175 million) in a Series C extension co-led by Sequoia Capital China, the VC arm of property developer Country Garden, Matrix Partners China and Co-Stone Capital.
China healthcare big data player LinkDoc raises $102m
LinkDoc Technology, a Chinese healthcare big data company, has raised RMB700 million ($102 million) in an extended Series D round from CICC Capital, Youshan Capital, and iFOF, a fund-of-funds launched by CBC Capital and the Tianjin government.
Vertex China closes first renminbi fund at $438m
Vertex China, a VC firm affiliated to Temasek Holdings-owned Vertex Holdings, has closed its first renminbi-denominated fund at RMB3 billion ($438 million).
China mixed reality player Nreal secures $40m Series B
Nreal, a Chinese manufacturers of advanced virtual reality glasses that resemble normal sunglasses, has raised $40 million in Series B funding led by local video sharing platform Kuaishou.
Chinese cleaning robot developer gets $22m Series B
Gaussian Robotics, a China-based developer of robots used for cleaning, has raised RMB150 million ($22 million) in an extended tranche of Series B round led by Broad Vision Funds and China Capital Management.
Sequoia leads Series B for Chinese coffee brand
Saturnbird, a Chinese coffee brand, has raised more than RMB100 million（$14 million) in a Series B funding round led by Sequoia Capital China. Existing backer Frees Fund re-upped.
Chinese drug developer Adlai Nortye raises $100m Series C
Adlai Nortye, a Chinese biopharma player specializing in cancer treatments, has raised nearly $100 million in Series C round led by Hong Kong-listed contrast research organisation (CRO) Tigermed and Shanghai-based Yingke PE.
China GPs must double down on operational skills - McKinsey
Private equity investors in China must develop new operational capabilities to deliver returns because they can no longer rely on macroeconomic tailwinds to drive growth, according to McKinsey & Company.
Qiming joins Series B for Chinese AI diagnosis player
Shukun, a Chinese start-up that develops artificial intelligence (AI) technology used in the medical imaging diagnosis, has raised RMB200 million in the third tranche of Series B round.
China data centers: Real estate plus
Valuations are rising in China’s data center industry as speculative real estate-style investors flood the market. Experienced players are willing to spend more time building scale
GL Ventures, Gaorong invest $80m in China's Kaikeba
Chinese vocational education platform Kaikeba has spun out from Huike Group and raised RMB550 million ($80 million) in Series A funding led by Gaorong Capital and GL Ventures, the VC unit of Hillhouse Capital.